Strides Pharma Science inks sub-license agreement with MPP

21 Mar 2022 Evaluate

Strides Pharma Science has entered into sub-license agreement with Medicines Patent Pool (MPP) to commercialize a generic version of Pfizer’s COVID-19 oral treatment in 95 low and middle-income markets.

Developed by Pfizer, the treatment is a SARS-CoV-2 main protease inhibitor oral antiviral therapy. The drug consists of nirmatrelvir tablets which are co-packaged and co-administered with ritonavir tablets. The product has been authorized as a Covid-19 oral therapy for emergency use in the U.S. and many other countries, both amongst high-risk adults and high-risk pediatric patients.

Branded as Kovidax, Strides’ generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with MPP. The product will be manufactured at Strides’ flagship facility in Bengaluru, and the Company has already secured its Active Pharmaceutical Ingredients (API) supplies through a preferred partnership arrangement.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1564.45 9.15 (0.59%)
01-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.